Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.79 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.79 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing market conditions affecting performance. They did not offer specific guidance for future quarters.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
The earnings report indicates that Mirum Pharmaceutical is facing challenges, as evidenced by the negative EPS. The stock reacted negatively, dropping nearly 7%, likely due to the lack of revenue details and future guidance. Investors may be cautious as the company navigates these uncertainties.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CRINETICS PHARMACEUT
Mar 9, 2020